Ipamorelin

• Community GH-secretagogue courserecommended

  Community practice, not from a label or trial. Low end of the 200-300 mcg range; no trial supports subcutaneous use.

• Trial (not self-dosing): 0.03 mg/kg IV twice daily from postoperative day 1 to day 7 or discharge, in 117 patients after bowel resection (Beck 2014).
• Community practice, not from a label or trial: 200-300 mcg per injection subcutaneously, 1-3 times daily (commonly twice daily), for 8-12 weeks, then 2-4 weeks off (Peptide Protocol Wiki; that page is internally inconsistent about the rest period).

Route: Subcutaneous injection (community). Trial: intravenous.

Timing: No reliable figure found in the sources; ask your prescriber or supplier.

• Bacteriostatic water is the diluent named by the secondary source, with no volume. The water in the protocol is arithmetic for a readable draw (2000 mcg + 2 mL gives 1000 mcg/mL, so 200 mcg = 20 units), not a sourced instruction.

No reliable figure found in the sources; ask your prescriber or supplier.

Community: 2-4 weeks off after 8-12 weeks.

Why:

• Figure from a secondary source that also says 4 weeks elsewhere; no trial supports a rest period.

• Never draw into the same syringe as another compound; use separate syringes and distinct injection sites.
• As described by the secondary source: often paired with CJC-1295 (no DAC) for a larger GH release, or with CJC-1295 DAC as a weekly partner. No human trial of the pair was fetched. Keep them in separate syringes.

Not FDA-approved for any indication; a research compound. Compounded and online supply is unverified.

Common side effects:

• Phase 2 IV trial: adverse events similar to placebo (87.5% vs 94.8%).
• Growth hormone secretagogues raise GH and IGF-1; people with active cancer, pituitary disease or diabetes should only use them under a prescriber.

Stop and call your prescriber if:

• Swelling, numbness or tingling in the hands
• Excessive thirst or urination
• Muscle weakness or palpitations

What sources report this compound changes, or say to check. A record of the evidence, not targets or advice.

• Time to tolerating solid foodReported changeHuman trial

  IV ipamorelin after bowel resection: median 25.3 h vs 32.6 h on placebo, not significant (p = 0.15); not a GH marker

  PubMed 25331030: phase 2 trial of ipamorelin for postoperative ileus (Beck 2014)

• PubMed 25331030: phase 2 trial of IV ipamorelin for postoperative ileus (Beck 2014)
• ClinicalTrials.gov NCT00672074: ipamorelin in post-operative ileus
• Peptide Protocol Wiki: ipamorelin (community protocol figures; secondary source)